FerroKin BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FerroKin BioSciences, Inc.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
The appointments of three device industry veterans to the Brookings-administered, and partially FDA-funded, Planning Board is intended to expand the range of input in the next phase of development of a new National Medical Device Surveillance System.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
There are approximately 140,000 fatalities a year from postpartum hemorrhage, mostly in low- to middle-income countries, and thus a pressing need to reduce mortality. A new low-pressure suction device from InPress Technologies Inc. that is inserted into the uterus following childbirth has the potential to initiate blood control within two minutes and reach full restoration of uterine tone in just over two hours.